Hasil Pencarian  ::  Simpan CSV :: Kembali

"Skripsi ini membahas tentang sebuah analisis perjanjian produk asuransi jiwa bernama Prulink Assurance Account Syariah, sebuah produk asuransi jiwa yang menyatukan tabungan masa depan dan proteksi jiwa. Rumusan masalah diangkat adalah membahas tentang hubungan hukum apa saja yang terjalin dalam perjanjian asuransi jiwa Prulink Assurance Account Syariah dan apakah Perjanjian Prulink Aasurance Account Syariah tersebut sesuai dengan hukum perikatan Islam. Penelitian ini menggunakan metode penelitian hukum normatif berdasarkan studi kepustakaan serta wawancara dengan Analisis kualitatif. Kesimpulan yang diperoleh adalah terdapat dua hubungan hukum dalam perjanjian Prulink Assurance Account Syariah ini, pertama antar sesama peserta dengan akad tabarru’ dan hubungan peserta dengan PT Prudential Indonesia dengan akad wakalah bil ujrah. Kesimpulan terakhir yang penulis dapat adalah perjanjian ini sesuai dengan Hukum Perikatan Islam.

---

This thesis discusses an agreement analysis of life insurance product called PRUlink Assurance Account Sharia, a life insurance product that brings together future savings and life protection. Formulation of the problem is discussed about the author adopted the legal relationship that exists between the insurer and the fellow participants among the participants with the insurance company. The next problem formulation is a discussion of the terms of the insurance agreement Engagement Law is a normative Islam.Metode taken based kepustakaan.Analisis study used qualitative analysis. The conclusion is that the author can occur in two legal relationships Assurance Account Sharia PRUlink agreement, the first between fellow participants with tabarru contract 'and participant relationships with companies such as PT Prudential Indonesia with wakalah bil last ujrah. The conclusion from author is this agreement in accordance with Islamic Contract Law."

"Penggunaan obat yang menghambat sistem renin-angiotensin adalah salah satu cara efektif dalam mengintervensi patogenesis kelainan-kelainan kardiovaskular dan ginjal khususnya dalam terapi hipertensi. Ide untuk menhambat sistem renin pada muaranya dengan renin inhibitor telah dimulai sejak lebih dari 30 tahun yang lalu. Renin inhibitor menghambat perubahan angiotensinogen menjadi angiotensin, yang selanjutnya mengurangi pembentukan peptida aktif angiotensin II. Generasi pertama (enalkiren) dan generasi kedua (remikiren) dari renin inhibitor yang secara oral aktif, tidak pernah digunakan secara klinis karena rendahnya bioavailabilitas oral dan lemahnya aktivitas anti hipertensinya. Saat ini aliskiren, non-peptida renin inhibitor pertama yang secara oral aktif dari generasi ketiga telah melalui uji klinik di fase III dan telah disetujui oleh U.S. Food and Drug Administration (FDA) pada bulan Maret 2007. Obat ini merupakan renin inhibitor pertama dengan indikasi hipertensi di Indonesia, suatu obat dengan bioavailabilitas oral, spesifi sitas dan efi kasi yang lebih baik. Makalah ini membahas perkembangan serta aspek farmakologi dari aliskiren.

---

AbstractThe use of drugs that inhibit the renin-angiotensin system is one of the effective way to intervene in the pathogenesis of cardiovascular and renal disorders, especially in hypertension treatment. The idea of blocking the renin system at its origin by renin inhibitor has existed for more than 30 years. Renin inhibitor supresses the covension of angiotensinogen into angiotensin, and further deacreases the generation of the active peptide angiotensin II. The first generation (enalkiren) and second generation (remikiren) of orally active renin inhibitors were never used clinically because of low bioavailability and weak blood pressure-lowering activity. At present, aliskiren is the fi rst non-peptide orally active renin inhibitor of the third generation to progress to phase III clinical trials and was approved by U.S. Food and Drug Administration (FDA) in March 2007. Aliskiren becomes the fi rst renin inhibitor with indications for the treatment of hypertension in Indonesia, a compounds with improved oral bioavailability, specifi city and effi cacy. This review summarises the development of oral renin inhibitors, pharmacological aspects, with a focus on aliskiren. "

"Indonesia's crisis began in July 1997, following the float of theThai's Bath and the Malaysia's Ringgit. As a consequence, unemploymentsoared into the millions as the crisis spread. The number of poor people rosedramatically around 22 million at early 1997 to about 79 million in themiddle of !998, according to the BPS estimation. In fact the pressure, whichled to the ultimate collapse office indonesia's economic miracle, began in liveearly 19905. Indonesia failed to sustain microeconomic reform after 1993.When Soeharto administration was re-inaugurated in 1993, economic growthwas back to above 6.5 percent, and investment was pouring in. The days of themega-project arrived. Two feature common to most of these mega-projectswere high capital requirements and their domestic market orientation.Inefficiency in the real sector due to high costs generated by the so-called?crony capitalism? also flourished. Despite several positive indications ofeconomic development, a more fundamental reform has not been touchedseriously, i.e. rise human capital improvement in health and education of :hepeople is of prime importance to raise labor productivity and turn will raisetheir earning and welfare."